Interleukin 33 is a guardian of barriers and a local alarmin

Nature Immunology

Volumn 17, Issue 2, 2016, Pages 122-131

  Martin, Nikolas T ^a   Martin, Michael U ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALARMIN; INTERLEUKIN 33; INTERLEUKIN 33 RECEPTOR; INTERLEUKIN RECEPTOR; NUCLEAR PROTEIN; UNCLASSIFIED DRUG; PROTEIN BINDING;

ADAPTIVE IMMUNITY; COMPLEX FORMATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GENE EXPRESSION REGULATION; HELPER CELL; HOMEOSTASIS; HUMAN; IMMUNITY; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; PROTEIN TRANSPORT;

ALARMINS; ANIMALS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERLEUKIN-33; PROTEIN BINDING; PROTEIN TRANSPORT; RECEPTORS, INTERLEUKIN; SIGNAL TRANSDUCTION;

EID: 84955159685     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3370     Document Type: Review

References (160)

1. Schmitz, J. et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23, 479-490 (2005).
2. Garlanda, C., Dinarello, C. A. & Mantovani, A. The interleukin-1 family: back to the future. Immunity 39, 1003-1018 (2013).
3. Priestle, J. P., Schär, H. P. & Grütter, M. G. Crystal structure of the cytokine interleukin-1b. EMBO J. 7, 339-343 (1988).
4. Lingel, A. et al. Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors-insight into heterotrimeric IL-1 signaling complexes. Structure 17, 1398-1410 (2009).
5. Afonina, I. S., Müller, C., Martin, S. J. & Beyaert, R. Proteolytic processing of interleukin-1 family cytokines: variations on a common theme. Immunity 42, 991-1004 (2015).
6. Boraschi, D. & Tagliabue, A. The interleukin-1 receptor family. Semin. Immunol. 25, 394-407 (2013).
7. Xu, D. et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J. Exp. Med. 187, 787-794 (1998).
8. Moritz, D. R., Rodewald, H. R., Gheyselinck, J. & Klemenz, R. The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J. Immunol. 161, 4866-4874 (1998).
9. Hoshino, K. et al. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J. Exp. Med. 190, 1541-1548 (1999).
10. Townsend, M. J., Fallon, P. G., Matthews, D. J., Jolin, H. E. & McKenzie, A. N. T1/ ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J. Exp. Med. 191, 1069-1076 (2000).
11. Senn, K. A. et al. T1-deficient and T1-Fc-transgenic mice develop a normal protective TH2-type immune response following infection with Nippostrongylus brasiliensis. Eur. J. Immunol. 30, 1929-1938 (2000).
12. Coyle, A. J. et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J. Exp. Med. 190, 895-902 (1999).
13. Liew, F. Y., Pitman, N. I. & McInnes, I. B. Disease-associated functions of IL-33: The new kid in the IL-1 family. Nat. Rev. Immunol. 10, 103-110 (2010).
14. Saluja, R. et al. The role of the IL-33/IL-1RL1 axis in mast cell and basophil activation in allergic disorders. Mol. Immunol. 63, 80-85 (2015).
15. Lopetuso, L. R., Chowdhry, S. & Pizarro, T. T. Opposing functions of classic and novel IL-1 family members in gut health and disease. Front. Immunol. 4, 181 (2013).
16. Palmer, G. & Gabay, C. Interleukin-33 biology with potential insights into human diseases. Nat. Rev. Rheumatol. 7, 321-329 (2011).
17. Gadani, S. P., Walsh, J. T., Smirnov, I., Zheng, J. & Kipnis, J. The glia-derived alarmin IL-33 orchestrates the immune response and promotes recovery following CNS injury. Neuron 85, 703-709 (2015).
18. Miller, A. M. & Liew, F. Y. The IL-33/ST2 pathway - A new therapeutic target in cardiovascular disease. Pharmacol. Ther. 131, 179-186 (2011).
19. Liew, F. Y. IL-33: A Janus cytokine. Ann. Rheum. Dis. 71 (suppl. 2), i101-i104 (2012).
20. Palomo, J., Dietrich, D., Martin, P., Palmer, G. & Gabay, C. The interleukin (IL)-1 cytokine family-balance between agonists and antagonists in inflammatory diseases. Cytokine 76, 25-37 (2015).
21. Onda, H. et al. Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. J. Cereb. Blood Flow Metab. 19, 1279-1288 (1999).
22. Baekkevold, E. S. et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am. J. Pathol. 163, 69-79 (2003).
23. Küchler, A. M. et al. Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am. J. Pathol. 173, 1229-1242 (2008).
24. Moussion, C., Ortega, N. & Girard, J.-P. P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: A novel 'alarmin'? PLoS ONE 3, e3331 (2008).
25. Sundlisaeter, E. et al. The alarmin IL-33 is a notch target in quiescent endothelial cells. Am. J. Pathol. 181, 1099-1111 (2012).
26. Talabot-Ayer, D. et al. Severe neutrophil-dominated inflammation and enhanced myelopoiesis in IL-33-overexpressing CMV/IL33 mice. J. Immunol. 194, 750-760 (2015).
27. Zhiguang, X. et al. Over-expression of IL-33 leads to spontaneous pulmonary inflammation in mIL-33 transgenic mice. Immunol. Lett. 131, 159-165 (2010).
28. Pichery, M. et al. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J. Immunol. 188, 3488-3495 (2012).
29. Sundnes, O. et al. Epidermal expression and regulation of interleukin-33 during homeostasis and inflammation: strong species differences. J. Invest. Dermatol. 135, 1771-1780 (2015).
30. Préfontaine, D. et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J. Allergy Clin. Immunol. 125, 752-754 (2010).
31. Louten, J. et al. Endogenous IL-33 enhances TH2 cytokine production and T-cell responses during allergic airway inflammation. Int. Immunol. 23, 307-315 (2011).
32. Carriere, V. et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl. Acad. Sci. USA 104, 282-287 (2007).
33. Roussel, L., Erard, M., Cayrol, C. & Girard, J.-P. P. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep. 9, 1006-1012 (2008).
34. Kakkar, R., Hei, H., Dobner, S. & Lee, R. T. Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J. Biol. Chem. 287, 6941-6948 (2012).
35. Bessa, J. et al. Altered subcellular localization of IL-33 leads to nonresolving lethal inflammation. J. Autoimmun. 55, 33-41 (2014).
36. Kalashnikova, A. A., Porter-Goff, M. E., Muthurajan, U. M., Luger, K. & Hansen, J. C. The role of the nucleosome acidic patch in modulating higher-order chromatin structure. J. R. Soc. Interface 10, 20121022 (2013).
37. Shao, D. et al. Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. Biochem. Biophys. Res. Commun. 451, 8-14 (2014).
38. Ali, S. et al. The dual function cytokine IL-33 interacts with the transcription factor NF-kB to dampen NF-kB-stimulated gene transcription. J. Immunol. 187, 1609-1616 (2011).
39. Choi, Y.-S. S. et al. Nuclear IL-33 is a transcriptional regulator of NF-kB p65 and induces endothelial cell activation. Biochem. Biophys. Res. Commun. 421, 305-311 (2012).
40. Shan, J. et al. Epithelial-derived nuclear IL-33 aggravates inflammation in the pathogenesis of reflux esophagitis. J. Gastroenterol. 50, 414-423 (2015).
41. Zhang, F. et al. Expression of IL-33 and its epigenetic regulation in multiple sclerosis. Ann. Clin. Transl. Neurol. 1, 307-318 (2014).
42. Tao, L. et al. Deubiquitination and stabilization of IL-33 by USP21. Int. J. Clin. Exp. Pathol. 7, 4930-4937 (2014).
43. Rider, P., Carmi, Y., Voronov, E. & Apte, R. N. Interleukin-1a. Semin. Immunol. 25, 430-438 (2013).
44. Polumuri, S. K. et al. Transcriptional regulation of murine IL-33 by TLR and non-TLR agonists. J. Immunol. 189, 50-60 (2012).
45. Talabot-Ayer, D. et al. The mouse interleukin (Il)33 gene is expressed in a cell type-and stimulus-dependent manner from two alternative promoters. J. Leukoc. Biol. 91, 119-125 (2012).
46. Tsuda, H. et al. Novel splice variants of IL-33: differential expression in normal and transformed cells. J. Invest. Dermatol. 132, 2661-2664 (2012).
47. Hong, J. et al. Identification of constitutively active interleukin 33 (IL-33) splice variant. J. Biol. Chem. 286, 20078-20086 (2011).
48. Meephansan, J., Tsuda, H., Komine, M., Tominaga, S. & Ohtsuki, M. Regulation of IL-33 expression by IFN-g and tumor necrosis factor - A in normal human epidermal keratinocytes. J. Invest. Dermatol. 132, 2593-2600 (2012).
49. Meephansan, J. et al. Expression of IL-33 in the epidermis: The mechanism of induction by IL-17. J. Dermatol. Sci. 71, 107-114 (2013).
50. Seltmann, J., Werfel, T. & Wittmann, M. Evidence for a regulatory loop between IFN-g and IL-33 in skin inflammation. Exp. Dermatol. 22, 102-107 (2013).
51. Kopach, P. et al. IFN-g directly controls IL-33 protein level through a STAT1-and LMP2-dependent mechanism. J. Biol. Chem. 289, 11829-11843 (2014).
52. Haraldsen, G., Balogh, J., Pollheimer, J., Sponheim, J. & Küchler, A. M. Interleukin-33-cytokine of dual function or novel alarmin? Trends Immunol. 30, 227-233 (2009).
53. Cayrol, C. & Girard, J.-P. P. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc. Natl. Acad. Sci. USA 106, 9021-9026 (2009).
54. Lüthi, A. U. et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31, 84-98 (2009).
55. Ali, S., Nguyen, D. Q., Falk, W. & Martin, M. U. Caspase 3 inactivates biologically active full length interleukin-33 as a classical cytokine but does not prohibit nuclear translocation. Biochem. Biophys. Res. Commun. 391, 1512-1516 (2010).
56. Talabot-Ayer, D., Lamacchia, C., Gabay, C. & Palmer, G. Interleukin-33 is biologically active independently of caspase-1 cleavage. J. Biol. Chem. 284, 19420-19426 (2009).
57. Madouri, F. et al. Caspase-1 activation by NLRP3 inflammasome dampens IL-33-dependent house dust mite-induced allergic lung inflammation. J. Mol. Cell Biol. 7, 351-365 (2015).
58. Rickard, J. A. et al. RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. Cell 157, 1175-1188 (2014).
59. Sanada, S. et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117, 1538-1549 (2007).
60. Chen, W.-Y. Y., Hong, J., Gannon, J., Kakkar, R. & Lee, R. T. Myocardial pressure overload induces systemic inflammation through endothelial cell IL-33. Proc. Natl. Acad. Sci. USA 112, 7249-7254 (2015).
61. Zhao, W. & Hu, Z. The enigmatic processing and secretion of interleukin-33. Cell. Mol. Immunol. 7, 260-262 (2010).
62. Lefrançais, E. & Cayrol, C. Mechanisms of IL-33 processing and secretion: differences and similarities between IL-1 family members. Eur. Cytokine Netw. 23, 120-127 (2012).
63. Lefrançais, E. et al. Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells. Proc. Natl. Acad. Sci. USA 111, 15502-15507 (2014).
64. Lefrançais, E. et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc. Natl. Acad. Sci. USA 109, 1673-1678 (2012).
65. Roy, A. et al. Mast cell chymase degrades the alarmins heat shock protein 70, biglycan, HMGB1, and interleukin-33 (IL-33) and limits danger-induced inflammation. J. Biol. Chem. 289, 237-250 (2014).
66. Cohen, E. S. et al. Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation. Nat. Commun. 6, 8327 (2015).
67. Zhao, W.-H. H. & Hu, Z.-Q. Q. Upregulation of IL-33 expression in various types of murine cells by IL-3 and IL-4. Cytokine 58, 267-273 (2012).
68. Su, Z. et al. Potential autocrine regulation of interleukin-33/ST2 signaling of dendritic cells in allergic inflammation. Mucosal Immunol. 6, 921-930 (2013).
69. Li, C. et al. Interleukin-33 increases antibacterial defense by activation of inducible nitric oxide synthase in skin. PLoS Pathog. 10, e1003918 (2014).
70. Demyanets, S. et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J. Mol. Cell. Cardiol. 60, 16-26 (2013).
71. Hu, X. & Ivashkiv, L. B. Cross-regulation of signaling pathways by interferon-g: implications for immune responses and autoimmune diseases. Immunity 31, 539-550 (2009).
72. Sugita, S. et al. Transcription factor Hes1 modulates osteoarthritis development in cooperation with calcium/calmodulin-dependent protein kinase 2. Proc. Natl. Acad. Sci. USA 112, 3080-3085 (2015).
73. Liang, Y. et al. IL-33 promotes innate IFN-g production and modulates dendritic cell response in LCMV-induced hepatitis in mice. Eur. J. Immunol. (2015).
74. Zhang, H.-F. F. et al. Altered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stress. J. Transl. Med. 10, 120 (2012).
75. Ali, S. et al. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc. Natl. Acad. Sci. USA 104, 18660-18665 (2007).
76. Chackerian, A. A. et al. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J. Immunol. 179, 2551-2555 (2007).
77. Palmer, G. et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine 42, 358-364 (2008).
78. Liu, X. et al. Structural insights into the interaction of IL-33 with its receptors. Proc. Natl. Acad. Sci. USA 110, 14918-14923 (2013).
79. Martin, M. U. Special aspects of interleukin-33 and the IL-33 receptor complex. Semin. Immunol. 25, 449-457 (2013).
80. Hayakawa, H., Hayakawa, M., Kume, A. & Tominaga, S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J. Biol. Chem. 282, 26369-26380 (2007).
81. Garlanda, C., Riva, F., Bonavita, E. & Mantovani, A. Negative regulatory receptors of the IL-1 family. Semin. Immunol. 25, 408-415 (2013).
82. Shimpo, M. et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 109, 2186-2190 (2004).
83. Pascual-Figal, D. A. & Januzzi, J. L. The biology of ST2: The international ST2 consensus panel. Am. J. Cardiol. 115 (suppl. ), 3B-7B (2015).
84. Mueller, T. & Jaffe, A. S. Soluble ST2-analytical considerations. Am. J. Cardiol. 115 (suppl. ), 8B-21B (2015).
85. Drube, S. et al. The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells. Blood 115, 3899-3906 (2010).
86. Klemenz, R., Hoffmann, S. & Werenskiold, A. K. Serum-and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen. Proc. Natl. Acad. Sci. USA 86, 5708-5712 (1989).
87. Tominaga, S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 258, 301-304 (1989).
88. Superti-Furga, G., Bergers, G., Picard, D. & Busslinger, M. Hormone-dependent transcriptional regulation and cellular transformation by Fos-steroid receptor fusion proteins. Proc. Natl. Acad. Sci. USA 88, 5114-5118 (1991).
89. Lanahan, A., Williams, J. B., Sanders, L. K. & Nathans, D. Growth factor-induced delayed early response genes. Mol. Cell. Biol. 12, 3919-3929 (1992).
90. Yanagisawa, K., Takagi, T., Tsukamoto, T., Tetsuka, T. & Tominaga, S. Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett. 318, 83-87 (1993).
91. Gächter, T., Werenskiold, A. K. & Klemenz, R. Transcription of the interleukin-1 receptor-related T1 gene is initiated at different promoters in mast cells and fibroblasts. J. Biol. Chem. 271, 124-129 (1996).
92. Löhning, M. et al. T1/ST2 is preferentially expressed on murine TH2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for TH2 effector function. Proc. Natl. Acad. Sci. USA 95, 6930-6935 (1998).
93. Guo, L. et al. IL-1 family members and STAT activators induce cytokine production by TH2, TH17, and TH1 cells. Proc. Natl. Acad. Sci. USA 106, 13463-13468 (2009).
94. Bonilla, W. V. et al. The alarmin interleukin-33 drives protective antiviral CD8+ T cell responses. Science 335, 984-989 (2012).
95. Baumann, C. et al. T-bet-and STAT4-dependent IL-33 receptor expression directly promotes antiviral TH1 cell responses. Proc. Natl. Acad. Sci. USA 112, 4056-4061 (2015).
96. Schiering, C. et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513, 564-568 (2014).
97. Spooner, C. J. et al. Specification of type 2 innate lymphocytes by the transcriptional determinant Gfi1. Nat. Immunol. 14, 1229-1236 (2013).
98. Zhao, J. et al. Focal adhesion kinase-mediated activation of glycogen synthase kinase-3b regulates IL-33 receptor internalization and IL-33 signaling. J. Immunol. 194, 795-802 (2015).
99. Zhao, J. et al. F-box protein FBXL19-mediated ubiquitination and degradation of the receptor for IL-33 limits pulmonary inflammation. Nat. Immunol. 13, 651-658 (2012).
100. Connolly, D. J., O'Neill, L. A. & McGettrick, A. F. The GOLD domain-containing protein TMED1 is involved in interleukin-33 signaling. J. Biol. Chem. 288, 5616-5623 (2013).
101. McGettrick, A. F. & O'Neill, L. A. Localisation and trafficking of Toll-like receptors: An important mode of regulation. Curr. Opin. Immunol. 22, 20-27 (2010).
102. Schmieder, A., Multhoff, G. & Radons, J. Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. Cytokine 60, 514-521 (2012).
103. Järås, M. et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc. Natl. Acad. Sci. USA 107, 16280-16285 (2010).
104. Barreyro, L. et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood 120, 1290-1298 (2012).
105. Pinto, S. M. et al. Quantitative phosphoproteomic analysis of IL-33-mediated signaling. Proteomics 15, 532-544 (2015).
106. Maywald, R. L. et al. IL-33 activates tumor stroma to promote intestinal polyposis. Proc. Natl. Acad. Sci. USA 112, E2487-E2496 (2015).
107. Pollheimer, J. et al. Interleukin-33 drives a proinflammatory endothelial activation that selectively targets nonquiescent cells. Arterioscler. Thromb. Vasc. Biol. 33, e47-e55 (2013).
108. Oboki, K. et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc. Natl. Acad. Sci. USA 107, 18581-18586 (2010).
109. Kim, H. Y. et al. Innate lymphoid cells responding to IL-33 mediate airway-hyperreactivity independent of adaptive immunity. J. Allergy Clin. Immunol. 129, 216-227 (2012).
110. Lei, Y. et al. Vaccination against IL-33 inhibits airway hyperresponsiveness and inflammation in a house dust mite model of asthma. PLoS ONE 10, e0133774 (2015).
111. Xu, D. et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc. Natl. Acad. Sci. USA 105, 10913-10918 (2008).
112. Palmer, G. et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 60, 738-749 (2009).
113. Martin, P. et al. Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency. Arthritis Res. Ther. 15, R13 (2013).
114. Talabot-Ayer, D. et al. Immune-mediated experimental arthritis in IL-33-deficient mice. Cytokine 69, 68-74 (2014).
115. Liu, X. et al. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem. Biophys. Res. Commun. 386, 181-185 (2009).
116. Lee, J. S., Seppanen, E., Patel, J., Rodero, M. P. & Khosrotehrani, K. ST2 receptor invalidation maintains wound inflammation, delays healing and increases fibrosis. Exp. Dermatol. (2015).
117. Lunderius-Andersson, C., Enoksson, M. & Nilsson, G. Mast cells respond to cell injury through the recognition of IL-33. Front. Immunol. 3, 82 (2012).
118. Hammad, H. & Lambrecht, B. N. Barrier epithelial cells and the control of type 2 immunity. Immunity 43, 29-40 (2015).
119. Divekar, R. & Kita, H. Recent advances in epithelium-derived cytokines (IL-33, IL-25, and thymic stromal lymphopoietin) and allergic inflammation. Curr. Opin. Allergy Clin. Immunol. 15, 98-103 (2015).
120. Rank, M. A. et al. IL-33-activated dendritic cells induce an atypical TH2-type response. J. Allergy Clin. Immunol. 123, 1047-1054 (2009).
121. Besnard, A.-G. G. et al. IL-33-activated dendritic cells are critical for allergic airway inflammation. Eur. J. Immunol. 41, 1675-1686 (2011).
122. Matta, B. M. et al. IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells. J. Immunol. 193, 4010-4020 (2014).
123. Williams, J. W. et al. Transcription factor IRF4 drives dendritic cells to promote TH2 differentiation. Nat. Commun. 4, 2990 (2013).
124. Tjota, M. Y. et al. Signaling through FcRg-associated receptors on dendritic cells drives IL-33-dependent TH2-type responses. J. Allergy Clin. Immunol. 134, 706-713 (2014).
125. Turnquist, H. R. R. & Thomson, A. W. IL-33 broadens its repertoire to affect DC. Eur. J. Immunol. 39, 3292-3295 (2009).
126. Turnquist, H. R. et al. IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J. Immunol. 187, 4598-4610 (2011).
127. Morita, H. et al. An interleukin-33-mast cell-interleukin-2 axis suppresses papain-induced allergic inflammation by promoting regulatory T cell numbers. Immunity 43, 175-186 (2015).
128. Hueber, A. J. et al. IL-33 induces skin inflammation with mast cell and neutrophil activation. Eur. J. Immunol. 41, 2229-2237 (2011).
129. Enoksson, M. et al. Intraperitoneal influx of neutrophils in response to IL-33 is mast cell-dependent. Blood 121, 530-536 (2013).
130. Komai-Koma, M et al. IL-33 activates B1 cells and exacerbates contact sensitivity. J. Immunol. 186, 2584-2591 (2011).
131. Ahmed, A. & Koma, M. K. Interleukin-33 triggers B1 cell expansion and its release of monocyte/macrophage chemoattractants and growth factors. Scand. J. Immunol. 82, 118-124 (2015).
132. Sattler, S. et al. IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut. J. Autoimmun. 50, 107-122 (2014).
133. Kurokawa, M. et al. Expression and effects of IL-33 and ST2 in allergic bronchial asthma: IL-33 induces eotaxin production in lung fibroblasts. Int. Arch. Allergy Immunol. 155 Suppl 1, 12-20 (2011).
134. Bianchetti, L. et al. IL-33 promotes the migration and proliferation of circulating fibrocytes from patients with allergen-exacerbated asthma. Biochem. Biophys. Res. Commun. 426, 116-121 (2012).
135. Hayashi, H. et al. IL-33 enhanced the proliferation and constitutive production of IL-13 and IL-5 by fibrocytes. BioMed Res. Int. 2014, 738625 (2014).
136. Kouzaki, H., Iijima, K., Kobayashi, T., O'Grady, S. M. & Kita, H. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J. Immunol. 186, 4375-4387 (2011).
137. Byers, D. E. et al. Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J. Clin. Invest. 123, 3967-3982 (2013).
138. Holtzman, M. J. et al. Linking acute infection to chronic lung disease. The role of IL-33-expressing epithelial progenitor cells. Ann. Am. Thorac. Soc. 11 (suppl. 5), S287-S291 (2014).
139. Paris, G., Pozharskaya, T., Asempa, T. & Lane, A. P. Damage-associated molecular patterns stimulate interleukin-33 expression in nasal polyp epithelial cells. Int. Forum Allergy Rhinol. 4, 15-21 (2014).
140. Zhang, L., Lu, R., Zhao, G., Pflugfelder, S. C. & Li, D.-Q. Q. TLR-mediated induction of pro-allergic cytokine IL-33 in ocular mucosal epithelium. Int. J. Biochem. Cell Biol. 43, 1383-1391 (2011).
141. Seidelin, J. B. et al. IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol. Lett. 128, 80-85 (2010).
142. Nomura, K. et al. Regulation of interleukin-33 and thymic stromal lymphopoietin in human nasal fibroblasts by proinflammatory cytokines. Laryngoscope 122, 1185-1192 (2012).
143. Sponheim, J. et al. Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am. J. Pathol. 177, 2804-2815 (2010).
144. Byrne, S. N., Beaugie, C., O'Sullivan, C., Leighton, S. & Halliday, G. M. The immune-modulating cytokine and endogenous Alarmin interleukin-33 is upregulated in skin exposed to inflammatory UVB radiation. Am. J. Pathol. 179, 211-222 (2011).
145. Wood, I. S., Wang, B. & Trayhurn, P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem. Biophys. Res. Commun. 384, 105-109 (2009).
146. Saidi, S. et al. IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling. Cytokine 53, 347-354 (2011).
147. Hudson, C. A. et al. Induction of IL-33 expression and activity in central nervous system glia. J. Leukoc. Biol. 84, 631-643 (2008).
148. Kempuraj, D. et al. Glia maturation factor induces interleukin-33 release from astrocytes: implications for neurodegenerative diseases. J. Neuroimmune Pharmacol. 8, 643-650 (2013).
149. Yasuoka, S. et al. Production and functions of IL-33 in the central nervous system. Brain Res. 1385, 8-17 (2011).
150. Hu, W. T. et al. IL-33 enhances proliferation and invasiveness of decidual stromal cells by up-regulation of CCL2/CCR2 via NF-?B and ERK1/2 signaling. Mol. Hum. Reprod. 20, 358-372 (2014).
151. Arshad, M. I. et al. TRAIL but not FasL and TNFa, regulates IL-33 expression in murine hepatocytes during acute hepatitis. Hepatology 56, 2353-2362 (2012).
152. Arshad, M. I. et al. Pathogenic mouse hepatitis virus or poly(I:C) induce IL-33 in hepatocytes in murine models of hepatitis. PLoS ONE 8, e74278 (2013).
153. Arshad, M. I. et al. NKT cells are required to induce high IL-33 expression in hepatocytes during ConA-induced acute hepatitis. Eur. J. Immunol. 41, 2341-2348 (2011).
154. Kim, L. K. et al. AMCase is a crucial regulator of type 2 immune responses to inhaled house dust mites. Proc. Natl. Acad. Sci. USA 112, E2891-E2899 (2015).
155. Préfontaine, D. et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J. Immunol. 183, 5094-5103 (2009).
156. Ohno, T. et al. Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J. Immunol. 183, 7890-7897 (2009).
157. Nile, C. J., Barksby, E., Jitprasertwong, P., Preshaw, P. M. & Taylor, J. J. Expression and regulation of interleukin-33 in human monocytes. Immunology 130, 172-180 (2010).
158. Yanagawa, Y., Suzuki, M., Matsumoto, M. & Togashi, H. Prostaglandin E(2) enhances IL-33 production by dendritic cells. Immunol. Lett. 141, 55-60 (2011).
159. Yanagawa, Y., Matsumoto, M. & Togashi, H. Adrenoceptor-mediated enhancement of interleukin-33 production by dendritic cells. Brain Behav. Immun. 25, 1427-1433 (2011).
160. Hsu, C.-L. L., Neilsen, C. V. & Bryce, P. J. IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS ONE 5, e11944 (2010).